Autolus has picked up its first ... (obecabtagene autoleucel or obe-cel) for the treatment of adults with relapsed or refractory B-cell precursor ALL based on the results of the phase 2 FELIX ...

Sales of the firm's cell therapy franchise grew modestly in the fourth quarter amid competing product launches and overall slow uptake within the class.

Autolus develops next-generation, programmed T cell therapies for the treatment of cancer. Its pipeline includes product candidates in development for the treatment of haematological malignancies ...

Aucatzyl is the first CAR-T cell therapy approved by the FDA with no requirement for a risk evaluation mitigation strategy (REMS) programme. Developer Autolus set a list price of $525,000 for its ...

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include ...

4 Institute of Pathology and Comprehensive Cancer Center EMN, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany Objectives CD19-targeting chimeric ...

2 The FDA approved the respective CAR T-cell therapy in November 2024 for the treatment of patients with relapsed/refractory ... Disclosures:Logan reported receiving research funding from Actinium, ...